Some stretch the period from seven days, initially to ten, then slowly increase the period, lowering their dependence on the GLP-1 medication
2 68% of patients were at very high risk for CKD progression 2,k Patient characteristics at baseline (N=3533) 1,2 k Patients were classified as very high risk for CKD progressing according to Kidney Disease: Improving Global Outcomes (KDIGO) risk calculators based on GFR and albuminuria categories
Talk with our team to explore pricing and payment options that work for you
At the 12-mg dose level, participants achieved a mean weight reduction of 17.5 percent at 24 weeks
Special population dosing considerations may apply to certain patient groups, though specific recommendations for the oral disintegrating tablet formulation may differ from those established for injectable tirzepatide
SADI-S/SIPS SADI-S is the same basic idea but with just one connection